Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease
Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease
复制标题
DOI：
10.1016/j.micinf.2018.03.002
复制
发表时间：
2018-05-01
影响因子：
5.8
通讯作者：
Pereira, Lygia Veiga
中科院分区：
文献类型：
--
作者：
Lara, Leonardo da Silva;Andrade-Lima, Leonardo;Pereira, Lygia Veiga
由克氏锥虫引起的恰加斯病是一个重要的全球公共卫生问题，尽管苯并硝唑在急性期有部分疗效，但迫切需要有效的治疗。心脏毒性是指导更准确的临床前药物筛选平台的主要安全问题。人类诱导多能干细胞衍生的心肌细胞（hiPSC-CM）是研究遗传和感染性心脏改变的可靠模型，并可能改善药物开发。在此，我们引入hiPSC-CM作为研究克氏t细胞心脏感染的合适模型，并预测抗t的安全性和有效性。cruzi药物。(C) 2018年巴斯德研究所。Elsevier Masson SAS出版。版权所有。
Chagas disease, caused by Trypanosoma cruzi, is an important global public health problem which, despite partial efficacy of benznidazole (Bz) in acute phase, urgently needs an effective treatment. Cardiotoxicity is a major safety concern for conduction of more accurate preclinical drug screening platforms. Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CM) are a reliable model to study genetic and infectious cardiac alterations and may improve drug development. Herein, we introduce hiPSC-CM as a suitable model to study T. cruzi heart infection and to predict the safety and efficacy of anti-T. cruzi drugs. (C) 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.